Xcout Intel
Sundance BioSciences
Sundance Biosciences is a biotechnology company founded in 2025 and headquartered in South San Francisco, California. The firm focuses on developing oral therapies that selectively target TYK2 to modulate immune responses for treating complex diseases.
Subscribe to see Sundance BioSciences’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Sundance BioSciences at a glance
Sundance BioSciences is a biotechnology company headquartered in United States. Its most recent funding round, Series B, closed in September 2025. Xcout tracks 8 named people at Sundance BioSciences, including Andrew Yost (Chief Executive Officer).
Sundance BioSciences leadership
- Andrew YostChief Executive Officer
- Steve WoodChief Scientific Officer
- Chetan GandhyExecutive Director, Clinical Development
- Andrew YostCEO
- Nancy StaglianoExecutive Chair
- Beth SeidenbergDirector
2 more named people on record for Sundance BioSciences, with roles, board committees and tenure — see the full roster →
Sundance BioSciences funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | Undisclosed | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Sundance BioSciences competitors
A few of Sundance BioSciences's closest competitors — see the full list of competitors and alternatives →
Ouro Medicines is a biotechnology company headquartered in South San Francisco, California, developing immune reset therapeutics for chronic immune-mediated diseases.
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Tizona Therapeutics, Inc. is a privately held immunology company founded in 2015 and headquartered in South San Francisco, California. The company focuses on harnessing the power of the immune system to develop treatments.
Dualitas Therapeutics is a privately held biotechnology research company headquartered in South San Francisco, California, that utilizes its DualScreen Bispecific Discovery Engine for proximity engagers.
Switch Therapeutics Inc. is a biotechnology company headquartered in South San Francisco, California. Founded in 2020, the company develops RNAi therapies based on its proprietary technology.
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis. Also included is OD-002, an oral small molecule SLC15A4 inhibitor engineered to prevent harmful inflammatory responses driven by TLR7/8/9-mediated activation of interferon regulatory factor 5 (IRF5). Another program, OD-003, is a protein therapeutic designed to selectively agonize tumor necrosis factor receptor 2 on T regulatory cells. Further assets in its portfolio comprise a bispecific antagonist targeting TSLP and IL-33, an oral small molecule functioning as an interleukin-1 receptor-associated kinase 4 scaffolding inhibitor, and a separate small molecule inhibitor specifically targeting IRF5. The company was founded in 2021 and is headquartered in Boston, Massachusetts.
Get Sundance BioSciences's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Sundance BioSciences in Xcout Intel
- 8 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access